Samsung C&T Corporation (KRX:028260) earned ₩2.00tn of net income in the first half of 2026. Over the same six months it reported ₩56.67tn of total comprehensive income.
The second number is twenty-eight times the first. In the second quarter alone the ratio was worse: ₩915.5bn of net income against ₩43.59tn of comprehensive income, a factor of forty-eight.
Total equity went from ₩57.50tn at the end of December to ₩113.71tn at the end of June. The company nearly doubled its book value in half a year while its actual operations produced about two trillion won of profit. Understanding the gap is most of what there is to understand about this stock.
Total assets went from ₩86.53tn to ₩163.77tn across the half. Nothing was built or bought at anything like that scale. Property, plant and equipment barely moved, from ₩9.67tn to ₩10.18tn. Intangibles actually fell slightly, from ₩5.96tn to ₩5.90tn. Purchases of property, plant and equipment for the entire half were ₩348.7bn.
Non-current assets, meanwhile, went from ₩65.18tn to ₩139.76tn. Strip out property and intangibles and roughly ₩124tn of that is something else. For Samsung C&T that something else is well known: the company holds the group's controlling blocks, including a large position in Samsung Life and stakes in other listed Samsung affiliates, and it also holds a Samsung Biologics position of consequence.
Under IFRS 9 a company may designate equity investments as measured at fair value through other comprehensive income. When it does, changes in the market price of those shares flow to OCI, not to profit and loss. That is the only mechanism that produces the pattern in these statements: an asset base that expands by ₩77tn while the income statement records ₩2tn.
So what happened is straightforward. Samsung Electronics and the other listed Samsung names have re-rated enormously through the memory and biologics cycles, and Samsung C&T marks its holdings to those prices every quarter. The summary financials don't itemise which stake contributed what, and the notes to the half-year report are where that detail sits.
There's a detail in the liabilities that most summaries skip and that neatly confirms the mechanism.
Total liabilities went from ₩29.04tn to ₩50.06tn over the half, with almost all of the increase in the non-current bucket, which moved from ₩15.16tn to ₩34.06tn. Samsung C&T did not borrow ₩19tn in six months. Cash from financing was negative ₩851bn.
Do the arithmetic on the whole balance sheet. Assets rose ₩77.24tn. Equity rose ₩56.21tn. Liabilities rose ₩21.02tn. That's 27.2% of the asset increase landing in liabilities, which is almost exactly the Korean corporate tax rate on the gains. The company has booked a deferred tax liability against unrealised appreciation it may never sell.
Which is worth pausing on. The ₩113.71tn of equity is already net of that tax. If Samsung C&T ever did dispose of these holdings, it would owe the tax, and the after-tax proceeds would be roughly what the book already says. The book is honest on that point. What it is not is available.
This is the part that catches people who are used to US GAAP.
When an equity investment is designated at fair value through OCI under IFRS 9, the accumulated gain is never recycled into profit or loss. Not when the price rises, not when it falls, and crucially not when the shares are sold. The gain moves within equity, from a revaluation reserve to retained earnings, and the income statement never sees it.
So the ₩56.67tn Samsung C&T booked this half will not appear in its earnings in any future period, under any circumstance. Anyone modelling a future year in which the company crystallises these positions and reports an enormous profit is modelling something the accounting standard forbids.
Retained earnings tell the same story from the other direction. They stood at ₩15.51tn at December 31 and ₩15.85tn at June 30, up ₩336bn while equity rose ₩56.21tn. The distributable pool barely moved, and distributable profit is the legal constraint on dividends and buybacks in Korea. A company can double its book value and not gain a won of capacity to return cash.
At the August 27 close of ₩375,500 across 162,167,581 common shares, Samsung C&T is capitalised at ₩60.89tn. Against ₩113.71tn of equity that is 0.54 times book, and the ratio has been falling as the book has risen.
The discount is not irrational. A holding structure whose principal assets are control blocks in affiliates cannot sell them, because selling them would surrender control of the Samsung group, which is the reason the structure exists. Marks on assets that will never be monetised are information about the group's value, not about what accrues to a Samsung C&T minority holder. Add the deferred tax already booked, add the Korean conglomerate discount, and half of book is roughly where the market has held this company for years.
What the discount does mean is that the price-to-book ratio has stopped carrying information. When the denominator moves 96% in six months on a mark, comparing the multiple to its own history or to peers tells you about Samsung Electronics' share price rather than about Samsung C&T.
Nothing about the mechanism is one-directional, and the recent past proves it.
In FY2024 Samsung C&T reported net income of ₩2.77tn and total comprehensive income of negative ₩2.23tn. In FY2022, net income of ₩2.54tn against comprehensive income of negative ₩2.42tn. Both years the operating business made money and the book value fell, because the marks went the other way.
So the same line that added ₩56.67tn this half has subtracted several trillion in two of the last four years. If the memory cycle turns and Samsung Electronics de-rates, Samsung C&T's equity will contract by tens of trillions of won without a single thing changing at its construction sites, its trading desk or Everland.
The steelman for taking the book seriously is that control blocks do occasionally get monetised, through group restructuring, holding-company conversion or forced disposal, and that Korean governance reform has made those outcomes more likely than they were a decade ago. If any of that happens, half of book is a genuinely low price for the underlying. That's a real possibility and it has been a real possibility for a very long time.
The retained earnings line, quarter by quarter. It is the only part of equity that governs what can be paid out, and it grew ₩336bn while total equity grew ₩56.21tn. If retained earnings start moving materially, something has been sold or restructured. If they keep crawling while book value swings by tens of trillions, the marks are decoration.
The second thing is the FY2026 annual report's note on financial assets at fair value through OCI, due next March. That note names the holdings and their carrying values. It will tell you exactly how much of this company is Samsung Life, how much is Samsung Biologics, and how much is everything else, which is the only way to know what you actually own.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.